Trial Profile
Post-marketing Surveillance of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix When Administered According to the Approved Prescribing Information in Korea
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2019
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Anal cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 21 Nov 2018 Status changed from not yet recruiting to recruiting.
- 20 Sep 2018 New trial record